[5]Peiffer DS, Howard FM, Chen N,et al. Epidemiology and Prognosis of HER2-Low Breast Cancer in the National Cancer Data Base. 2022 SABCS. HER2-11. [6]Viale G, Basik M, Nikura N,et al.Retrospective Study to Estimate the ...
[1]Jiaxian Miao, Jiuyan Shang, Yueping Liu, A New Scoring Algorithm to Assess the Prognosis of Primary and Metastatic Breast Cancer with HER2-low Expression. 2024USCAP. ABSTRACT 187. 审批编号:CN-147721 有效期至:2025-11-24 本材料由阿斯利康提供,仅供医疗卫生专业人士参考...
参考文献: [1]Jiaxian Miao, Jiuyan Shang, Yueping Liu, A New Scoring Algorithm to Assess the Prognosis of Primary and Metastatic Breast Cancer with HER2-low Expression. 2024USCAP. ABSTRACT 187. 审批编号:CN-147721 有效期...
Traditionally, the HER2-low entity was classified as HER2-negative when evaluating prognosis and administrating treatment in patients with breast cancer brain metastasis (BCBM). Trastuzumab deruxtecan (T-DXd) was proved to have potent efficacy in HER2-low breast cancer, even with brain metastasis,...
4. Agostinetto E, Rediti M, Fimereli D, et al. HER2-Low Breast Cancer: Molecular Characteristics and Prognosis. Cancers (Basel). 2021 Jun 5;13(11):2824. 5. Miglietta F, Griguolo G, Bottosso M, et al. Evolution of HER2-low expression from primary to recurrent breast cancer[J]. ...
4 Horisawa N, Adachi Y, Takatsuka D, Nozawa K, Endo Y,Ozaki Y, et al. The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. Breast Cancer 2022;2:234e41. https://doi.org/10.10...
Furthermore, they concluded that patients with HER2low breast cancer have a better prognosis compared to HER2- cases, in the ER- cohort. Other previous studies reported that HER2low is associated with worse prognosis, in ER+ breast cancer7,30. This is the first study that analyzes the ...
[8] Horisawa N, Adachi Y, Takatsuka D, et al. The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. Breast Cancer 2022;29(2):234-41. ...
The classification, he explained, would need to have a "unique biology" and be reliably defined, using a "robust assay." It would also need to have a "clinical impact," in that it should be associated with a "unique prognosis" and could be managed with a "unique treatment plan."...
A new editorial paper titled "HER2-low and HER2-zero in breast cancer between prognosis, prediction and entity" has been published in Oncotarget.